Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 119

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 119
---
 or any other country or region in the world (or escalation or worsening of any of the foregoing) including, in each case, the response of governmental authorities (except in each case to 
 the extent that such Effect has had a disproportionate adverse effect on Aadi Sub relative to other similarly situated companies operating in the industries in which Aadi Sub conducts business, in which case only the incremental disproportionate     
 adverse impact of such Effect on Aadi Sub as compared to the impact of such Effect on such other similarly situated companies may be taken into account in determining whether a Company Material Adverse Effect has occurred);                           |

- 75 -

| • |     | pandemics, epidemics, contagious disease outbreaks or other comparable events (or escalation or worsening of any                                                                                                                                     
 such events or occurrences), including, in each case, any action taken or not taken as required by any law, governmental authority or otherwise to respond to the impact, presence, outbreak or spread of any pandemic, epidemic, contagious disease 
 outbreaks or other comparable event;                                                                                                                                                                                                                 |

| • |     | any Effect resulting from the execution or announcement of the Divestiture Agreement (including the identity of                                                                                                                                        
 the parties) or the pendency or completion of the Divestiture or the other transactions contemplated by the Divestiture Agreement, including the impact thereof on the relationships, contractual or otherwise, of Aadi Sub with employees, suppliers, 
 customers, partners, vendors, governmental authorities or any other person (provided, however, that this exception shall not apply to the extent arising from any breach or inaccuracy of any representation or warranty set forth in the Divestiture  
 Agreement expressly addressing the authorization, execution and delivery of the Divestiture Agreement by Aadi Sub or the performance by Aadi Sub of its obligations thereunder, or any condition as it relates to such representation or warranty);    |

| • |     | the compliance by Aadi or Aadi Sub with the terms of the Divestiture Agreement, including any action taken or 
 refrained from being taken pursuant to or in accordance with the Divestiture Agreement;                       |

| • |     | any action taken or refrained from being taken, in each case to which Kaken has expressly approved, consented to 
 or requested in writing (including by email) following the date of the Divestiture Agreement;                    |

| • |     | changes or proposed changes in GAAP or other accounting standards or law (or the enforcement or interpretation of                                                                                               
 any of the foregoing), changes in the regulatory accounting requirements